141 related articles for article (PubMed ID: 15811173)
1. A study of the in vitro interaction between lidocaine and premedications using human liver microsomes.
Nagashima A; Tanaka E; Inomata S; Honda K; Misawa S
J Clin Pharm Ther; 2005 Apr; 30(2):185-8. PubMed ID: 15811173
[TBL] [Abstract][Full Text] [Related]
2. A study of the in vitro clinical interaction between lidocaine and premedications using rat liver microsomes.
Nagashima A; Tanak E; Inomata S; Misawa S
Hum Exp Toxicol; 2002 Aug; 21(8):453-6. PubMed ID: 12412639
[TBL] [Abstract][Full Text] [Related]
3. Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2', 6'-Pipecoloxylidide, on human liver microsomes in vitro.
Tanaka E; Nakamura T; Inomata S; Honda K
Basic Clin Pharmacol Toxicol; 2006 Feb; 98(2):181-3. PubMed ID: 16445592
[TBL] [Abstract][Full Text] [Related]
4. Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro.
Tanaka E; Takano Y; Inomata S; Toyooka H; Honda K
Eur J Clin Pharmacol; 2004 Oct; 60(8):565-8. PubMed ID: 15351923
[TBL] [Abstract][Full Text] [Related]
5. Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination.
Brown HS; Chadwick A; Houston JB
Drug Metab Dispos; 2007 Nov; 35(11):2119-26. PubMed ID: 17724064
[TBL] [Abstract][Full Text] [Related]
6. Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Wang JS; Backman JT; Wen X; Taavitsainen P; Neuvonen PJ; Kivistö KT
Pharmacol Toxicol; 1999 Nov; 85(5):201-5. PubMed ID: 10608481
[TBL] [Abstract][Full Text] [Related]
7. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
9. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
[TBL] [Abstract][Full Text] [Related]
10. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.
Manchee GR; Eddershaw PJ; Ranshaw LE; Herriott D; Park GR; Bayliss MK; Tarbit MH
Drug Metab Dispos; 1996 May; 24(5):555-9. PubMed ID: 8723736
[TBL] [Abstract][Full Text] [Related]
11. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.
Jamis-Dow CA; Klecker RW; Katki AG; Collins JM
Cancer Chemother Pharmacol; 1995; 36(2):107-14. PubMed ID: 7767945
[TBL] [Abstract][Full Text] [Related]
13. Metabolic interactions of magnolol with cytochrome P450 enzymes: uncompetitive inhibition of CYP1A and competitive inhibition of CYP2C.
Kim SB; Kang HE; Cho HJ; Kim YS; Chung SJ; Yoon IS; Kim DD
Drug Dev Ind Pharm; 2016; 42(2):263-9. PubMed ID: 26133083
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro.
Iwase M; Kurata N; Ehana R; Nishimura Y; Masamoto T; Yasuhara H
Hum Exp Toxicol; 2006 Dec; 25(12):715-21. PubMed ID: 17286149
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
Prueksaritanont T; Gorham LM; Ma B; Liu L; Yu X; Zhao JJ; Slaughter DE; Arison BH; Vyas KP
Drug Metab Dispos; 1997 Oct; 25(10):1191-9. PubMed ID: 9321523
[TBL] [Abstract][Full Text] [Related]
16. [The inhibition of lidocaine metabolism by various barbiturates in rat hepatic microsome].
Kakinohana M; Taira Y; Kakinohana O; Okuda Y
Masui; 1998 Nov; 47(11):1302-10. PubMed ID: 9852692
[TBL] [Abstract][Full Text] [Related]
17. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
18. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite.
Fischer V; Rodríguez-Gascón A; Heitz F; Tynes R; Hauck C; Cohen D; Vickers AE
Drug Metab Dispos; 1998 Aug; 26(8):802-11. PubMed ID: 9698296
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human liver cytochrome P-450 1A2 by the class IB antiarrhythmics mexiletine, lidocaine, and tocainide.
Wei X; Dai R; Zhai S; Thummel KE; Friedman FK; Vestal RE
J Pharmacol Exp Ther; 1999 May; 289(2):853-8. PubMed ID: 10215663
[TBL] [Abstract][Full Text] [Related]
20. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
Atkinson A; Kenny JR; Grime K
Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
